COMPANY PROFILE

Sidewinder Therapeutics

Explore full profile

Precision biologics targeting molecular drivers of cancer and rare diseases

San Diego, United StatesFounded 2023Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Sidewinder Therapeutics

Sidewinder Therapeutics is a biotechnology company dedicated to developing precision biologics aimed at treating cancer and rare diseases. The company operates in the therapeutics market, focusing on large molecule drugs that target specific molecular drivers of disease. Sidewinder's business model revolves around drug discovery and development, leveraging the expertise of a dynamic team of serial entrepreneurs and expert scientists. Revenue is generated through the advancement and commercialization of innovative medicines designed to improve patient outcomes. The company serves patients with unmet medical needs, particularly those suffering from complex conditions that require targeted therapeutic interventions. Sidewinder's commitment to delivering life-saving therapies is underscored by its leadership team's extensive experience in the field.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2023
Headquarters: San Diego, United States
Employees: 9
Open positions: None listed
Dealroom signal: 64.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Antibodies, Biotech and Pharma, Antibody-Drug Conjugate, AI Drug Discovery, DT and LS
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Apr 2026	$137M	$548M	Longwood Fund · Astellas Venture · Alexandria Venture Investments · Goldman Sachs Asset Management	↗
SERIES AOther financing	Feb 2023	$25M	$100M	OrbiMed	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Sidewinder Therapeutics website traffic

Latest recorded traffic for Sidewinder Therapeutics is 2.9K monthly website visits, down 6.5% over the last three months. Sidewinder Therapeutics's team grew 12.5% over the past year.

Latest monthly visits2.9K 3-month web change-6.5% 1-year team growth+12.5%

Monthly website visitsApr 2025–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PBPunozhi Pharmaceutical BiotechnologyAI-powered drug discovery for hard-to-drug targets	China	Operational	—	—	—
BIBiologics4UAI-powered platforms for antibody and ADC drug discovery	Seoul, South Korea	Operational
SBShizhiyuan BiotechnologyInnovative monoclonal antibody drug development and manufacturing	China	Operational
EXExonicAI-native platform for biological molecule drug discovery	San Francisco, United States	Operational
NBNeologics BioscienceClinical-stage immuno-modulating antibody therapeutics for cancer	Changzhou, China	Operational
TATres AlchemixAI-powered drug discovery platform using quantum chemical calculations	Fukuoka, Japan	Operational
RBRidge BiotechnologiesAI-enabled platform for precision enzyme and drug design	Palo Alto, United States	Operational
ABAdcoris BioPharmaNext-generation antibody-drug conjugates for oncology	China	Operational